Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future()

To date, no effective adjuvant treatment for renal cell carcinoma (RCC) has been described, but research in this area is important since the 5-year relapse rate for intermediate- and high-risk early-stage RCC is 30%–40%. Metastatic RCC can be treated successfully with immune therapy and targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales: Janowitz, Tobias, Welsh, Sarah J., Zaki, Kamarul, Mulders, Peter, Eisen, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765962/
https://www.ncbi.nlm.nih.gov/pubmed/23972712
http://dx.doi.org/10.1053/j.seminoncol.2013.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765962/
https://www.ncbi.nlm.nih.gov/pubmed/23972712
http://dx.doi.org/10.1053/j.seminoncol.2013.05.004

Ejemplares similares